Product Description
JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody, is used in patients with advanced cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05296772)
Mechanisms of Action: IL21 Antagonist, Albumin Antagonist
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Anwita Biosciences
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06882876 |
JS014-F01 | P1 |
Enrolling by invitation |
Hepatocellular Carcinoma |
2027-01-01 |
2025-09-20 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/28/2021 |
News Article |
Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 |